Posted by ABMN Staff on Mar 19th, 2024
HC Wainwright reissued their buy rating on shares of aTyr Pharma (NASDAQ:LIFE – Free Report) in a research note published on Friday, Benzinga reports. The firm currently has a $35.00 price target on the biotechnology company’s...
More of this article »